• FujiFilm Medical Systems (Stamford, Connecticut) and FujiFilm SonoSite (Bothell, Washington) has introduced new digital radiography detectors, FDR D-EVO II and its high-resolution ultrasound kiosk, the X-Porte at the AAOS meeting. The new FDR-DEVO II detectors are completely redesigned, featuring many new and unique enhancements including: new IPX6 water resistance, improved battery life, improved dose efficiency, and a new internal memory function which stores up to 100 images. Built for real world imaging, these detectors are 20% lighter than prior models, making them among the world's lightest for their sizes. They are built to last and perform, incorporating durable magnesium alloy enclosure with a sleek surface and tapered edges to simplify technologist handling and positioning under the patient. FDR D-EVO II is also the world's first detector layered with an antibacterial silver ion coating engineered by Fujifilm and tested to be 100 times more effective than conventional coatings and provide 10,000 times more protection than surfaces with no coatings, the company said.

• Pathway Genomics (San Diego) has launched ColoTrue, a comprehensive panel that combines next-generation sequencing with deletion/duplication analysis to detect pathogenic variants in 15 high-risk colorectal cancer susceptibility genes. Pathway has also launched a smaller panel, LynchSyndromeTrue, which tests for Lynch syndrome, the most common form of hereditary colon cancer. While most colorectal cancer occurs sporadically, about 5% of cases are due to a hereditary genetic change that can be passed down through families. ColoTrue uses sequencing and deletion/duplication analysis to look for pathogenic variants in a wide range of genes implicated in hereditary colorectal cancer, including APC, BMPR1, CDH1, CHEK2, EPCAM (deletion/duplication only), MDM2 (SNP–309 single-site analysis only), MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, SMAD4, STK11, and TP53. LynchSyndromeTrue is a panel designed specifically for patients with features highly suggestive of Lynch syndrome. LynchSyndromeTrue tests five genes associated with Lynch syndrome, and can be reflexed to ColoTrue if no pathogenic variants are found. The addition of reflex testing allows clinicians to appropriately utilize panel testing without creating unnecessary costs for patients and insurance companies.

• pSivida (Watertown, Massachusetts) has completed the originally targeted enrollment of 120 patients in its pivotal Phase III clinical trial of Medidur for the treatment of posterior uveitis, a blinding eye disease. pSivida will permit 10 additional patients seeking entry into the trial who met the entry criteria to enroll. pSivida expects to report top line data from the trial in the second half of 2016, and based on the results, to file for regulatory approval in late 2016 or early 2017. Medidur is an injectable micro-insert delivering the steroid flucinolone acetonide (FA) on a sustained basis for 36 months.

• Sage Science (Beverly, Massachusetts) reported the launch of a proteomics early access program for its SageELF technology. SageELF is a protein sample prep tool useful for biomarker discovery, protein profiling, shotgun proteomics, quality control of biotherapeutics, and more. With this early access program, Sage Science expands the applications of the SageELF instrument from whole-sample DNA fractionation to protein fractionation for proteomic workflows. The SageELF generates 12 contiguous fractions from a protein sample in a fully automated process that is more sensitive and reproducible than manual 1D gels. The tool can be used to reduce sample complexity, enrich for rare proteins, and improve recovery of all proteins in a sample. The SageELF, short for Electrophoretic Lateral Fractionator, automatically electrophoreses samples and elutes proteins from the entire gel lane into 12 elution modules. Users simply load their sample, start the run, and pipette out the fractions later. Unlike in-gel digestion, in which some peptides never leave the gel, the whole protein sample is electrophoresed into the elution modules.

• Stryker's Spine Division (Allendale, New Jersey) has received FDA clearance for the LITe Plate System, an Anterior and Lateral Lumbar Plate System at AAOS. Comprised of five one-level, slim lumbar plates, the LITe Plate System features the WingSpring locking mechanism, a high degree of screw angulation, and simplified instrumentation. With this product introduction, Stryker Spine strengthens their ALIF product portfolio featuring Aero-AL and the LITe Anterior Retractor. Aero-AL is currently the only in-line Anchor-based ALIF device that compresses across the interbody.

• Wright Medical (Memphis, Tennessee) received FDA clearance to start marketing a new external fixation device designed to position foot and ankle bones during surgery. The company's latest regulatory win is for its Salvation external fixation system, a metal exoskeleton made of tensioned thin wires, half pins and metal rings that helps position the foot and lower leg during surgery. The device is designed to be used on its own or with other Salvation limb salvage products to treat fractures, non-connected bones and also foot/ankle deformities. The whole Salvation product line is indicated to treat a condition known as neuropathic osteoarthropathy or Charcot foot, a deformity involving collapse of the foot stemming from foot or ankle-related nerve damage.